Researchers at Novo Nordisk Discuss Findings in GLP-1 Receptor Agonist (A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK)

Source :: Obesity, Fitness & Wellness Week. March 1, 2020, 236
Publication Year :: 2020
Abstract: 2020 FEB 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Drugs and Therapies - GLP-1 Receptor Agonist are presented [...]

Subjects :: Novo Nordisk A/S -- Reports
Exenatide -- Reports
Physical fitness -- Reports
Liraglutide -- Reports
Type 2 diabetes -- Reports
Biochemistry -- Reports
Body weight -- Reports
Pharmaceutical industry -- Reports
Glycosylated hemoglobin -- Reports
Dulaglutide -- Reports
Semaglutide -- Reports
Glucagon
Clinical trials
Obesity
Peptides
Hemoglobins
Editors
Hypoglycemic agents
Health

Tools